Compare Teucrium Soybean Fund (SOYB) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Teucrium Soybean Fund vs TransMedics Group Inc — how do they compare? Teucrium Soybean Fund trades at $25.86, while TransMedics Group Inc trades at $74.78 (market cap $2.54B). The key difference: Teucrium Soybean Fund is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals.
| SOYB | TMDX | |
|---|---|---|
Sector | Commodities - Metals/Agriculture | Technology |
52-Week High | $25.88 | $150.42 |
52-Week Low | $21.07 | $61.99 |
Market Cap | — | $2.54B |
Enterprise Value | — | $2.94B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SOYB trades at $25.88, up 1.53% today, with a bullish technical outlook supported by moving averages. The stock shows strong momentum indicators but lacks available financial ratio data. Recent news highlights potential tailwinds from China's $17 billion U.S. crop purchase pledge through 2028, which may benefit agricultural sector stocks.
The stock's outlook is cautiously optimistic due to positive technical signals and favorable sector news, but investment is tempered by absent fundamental metrics and reliance on broader agricultural market trends. Key risks include commodity price volatility and execution uncertainties in trade agreements.
TransMedics (TMDX) is trading at $73.47, down 0.69% on the day, amid a mixed technical and fundamental backdrop. The stock shows neutral technical signals with support near $72 and resistance at $75, while fundamentals are strong with a trailing P/E of 16.81 and robust profitability metrics like a 27.04% net income margin. Recent earnings saw a Q1 2026 miss but beats in prior quarters, and the company is expanding in Europe through strategic investments.
The outlook is cautiously optimistic with a consensus price target of $108.71 implying significant upside, supported by 75% analyst buy ratings. Key risks include margin pressure from expansion costs and competitive threats, but the company's organ transplant logistics network offers a durable competitive advantage for long-term growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Teucrium Soybean Fund
SOYB is a commodity ETF that provides exposure to the price of soybean futures. It utilizes a laddered strategy by investing in several benchmark futures contracts to reduce the impact of roll costs and contango in the agricultural market.
Read more on SOYB →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
